David Risinger
Stock Analyst at Leerink Partners
(3.64)
# 802
Out of 5,055 analysts
172
Total ratings
66.67%
Success rate
15.62%
Average return
Main Sectors:
Stocks Rated by David Risinger
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Upgrades: Outperform | $886 → $1,104 | $1,025.28 | +7.68% | 17 | Nov 10, 2025 | |
| IMA ImageneBio | Initiates: Outperform | $30 | $8.10 | +270.37% | 1 | Oct 24, 2025 | |
| HALO Halozyme Therapeutics | Upgrades: Market Perform | $70 | $70.03 | -0.04% | 4 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Outperform | $458 → $456 | $437.15 | +4.31% | 5 | Sep 25, 2025 | |
| ROIV Roivant Sciences | Maintains: Outperform | $18 → $22 | $20.29 | +8.43% | 5 | Sep 18, 2025 | |
| JNJ Johnson & Johnson | Downgrades: Market Perform | $169 → $153 | $195.93 | -21.91% | 4 | May 13, 2025 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $762 → $834 | $693.50 | +20.26% | 9 | Feb 5, 2025 | |
| ABBV AbbVie | Upgrades: Outperform | $206 | $232.36 | -11.34% | 7 | Nov 22, 2024 | |
| BMY Bristol-Myers Squibb Company | Upgrades: Outperform | $55 → $73 | $46.65 | +56.48% | 4 | Nov 12, 2024 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $49 → $69 | $18.54 | +272.17% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $7.10 | +125.35% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $27.08 | +62.48% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $106 → $153 | $48.69 | +214.23% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $15 → $10 | $17.37 | -42.43% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $47 | $33.82 | +38.97% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $267 → $318 | $336.74 | -5.57% | 4 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $11 | $27.61 | -60.16% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $81 → $91 | $125.02 | -27.21% | 3 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $49 → $48 | $25.06 | +91.54% | 14 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $35 → $37 | $7.53 | +391.37% | 2 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $162 → $176 | $141.07 | +24.76% | 3 | Apr 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $16 | $10.72 | +49.25% | 1 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $53 → $45 | $13.78 | +226.56% | 17 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $22 → $35 | $6.28 | +457.32% | 4 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $41 | $21.09 | +94.40% | 5 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $167 → $174 | $120.82 | +44.02% | 9 | Nov 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $51 | $39.16 | +30.23% | 1 | Jul 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $13 → $8 | $25.41 | -68.52% | 19 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $97 → $89 | $92.92 | -4.22% | 8 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $11.64 | -74.23% | 4 | Apr 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $16 | $29.04 | -44.90% | 9 | Apr 2, 2020 |
Eli Lilly and Company
Nov 10, 2025
Upgrades: Outperform
Price Target: $886 → $1,104
Current: $1,025.28
Upside: +7.68%
ImageneBio
Oct 24, 2025
Initiates: Outperform
Price Target: $30
Current: $8.10
Upside: +270.37%
Halozyme Therapeutics
Oct 14, 2025
Upgrades: Market Perform
Price Target: $70
Current: $70.03
Upside: -0.04%
Vertex Pharmaceuticals
Sep 25, 2025
Upgrades: Outperform
Price Target: $458 → $456
Current: $437.15
Upside: +4.31%
Roivant Sciences
Sep 18, 2025
Maintains: Outperform
Price Target: $18 → $22
Current: $20.29
Upside: +8.43%
Johnson & Johnson
May 13, 2025
Downgrades: Market Perform
Price Target: $169 → $153
Current: $195.93
Upside: -21.91%
Regeneron Pharmaceuticals
Feb 5, 2025
Upgrades: Outperform
Price Target: $762 → $834
Current: $693.50
Upside: +20.26%
AbbVie
Nov 22, 2024
Upgrades: Outperform
Price Target: $206
Current: $232.36
Upside: -11.34%
Bristol-Myers Squibb Company
Nov 12, 2024
Upgrades: Outperform
Price Target: $55 → $73
Current: $46.65
Upside: +56.48%
Tectonic Therapeutic
Nov 11, 2024
Maintains: Outperform
Price Target: $49 → $69
Current: $18.54
Upside: +272.17%
Oct 24, 2024
Initiates: Outperform
Price Target: $16
Current: $7.10
Upside: +125.35%
Sep 17, 2024
Initiates: Outperform
Price Target: $44
Current: $27.08
Upside: +62.48%
Sep 3, 2024
Maintains: Outperform
Price Target: $106 → $153
Current: $48.69
Upside: +214.23%
Aug 6, 2024
Downgrades: Market Perform
Price Target: $15 → $10
Current: $17.37
Upside: -42.43%
Apr 16, 2024
Initiates: Outperform
Price Target: $47
Current: $33.82
Upside: +38.97%
Oct 11, 2023
Upgrades: Outperform
Price Target: $267 → $318
Current: $336.74
Upside: -5.57%
Aug 15, 2023
Maintains: Outperform
Price Target: $6 → $11
Current: $27.61
Upside: -60.16%
Feb 3, 2023
Maintains: Market Perform
Price Target: $81 → $91
Current: $125.02
Upside: -27.21%
Feb 1, 2023
Maintains: Market Perform
Price Target: $49 → $48
Current: $25.06
Upside: +91.54%
Feb 22, 2022
Maintains: Equal-Weight
Price Target: $35 → $37
Current: $7.53
Upside: +391.37%
Apr 1, 2021
Maintains: Equal-Weight
Price Target: $162 → $176
Current: $141.07
Upside: +24.76%
Mar 10, 2021
Maintains: Equal-Weight
Price Target: $18 → $16
Current: $10.72
Upside: +49.25%
Mar 5, 2021
Maintains: Equal-Weight
Price Target: $53 → $45
Current: $13.78
Upside: +226.56%
Feb 26, 2021
Maintains: Equal-Weight
Price Target: $22 → $35
Current: $6.28
Upside: +457.32%
Nov 24, 2020
Maintains: Overweight
Price Target: $31 → $41
Current: $21.09
Upside: +94.40%
Nov 13, 2020
Maintains: Equal-Weight
Price Target: $167 → $174
Current: $120.82
Upside: +44.02%
Jul 13, 2020
Initiates: Equal-Weight
Price Target: $51
Current: $39.16
Upside: +30.23%
Apr 2, 2020
Maintains: Underweight
Price Target: $13 → $8
Current: $25.41
Upside: -68.52%
Apr 2, 2020
Maintains: Overweight
Price Target: $97 → $89
Current: $92.92
Upside: -4.22%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $11.64
Upside: -74.23%
Apr 2, 2020
Maintains: Equal-Weight
Price Target: $20 → $16
Current: $29.04
Upside: -44.90%